Rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: A case report

Y. Yoshida, T. Ikegami, T. Yoshizumi, T. Toshima, Y. I. Yamashita, S. Yoshiya, K. Shirabe, Y. Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. However, it has never been reported that pre-LDLT genetic analyses of both host and virus, with prediction of the outcome of post-LDLT antiviral treatment, indicated LDLT for a borderline case.

Case Report We have reported the case of a 68-year-old woman with liver cirrhosis caused by genotype 1b hepatitis C, a history of ruptured esophageal varices, and adequately controlled minor ascites. Her liver function was classified as Child-Pugh grade B. The donor was a 42-year-old woman with an estimated left lobe graft volume (GV) of 33.8% based on the standard liver volume of the recipient. Molecular analyses used to confirm the indication of LDLT for this combination revealed the following: The rs8099917 genotype was T/T in the donor and recipient, the HCV core protein was double wild type, there were no mutations in the interferon sensitivity-determining region, and 8 mutations were found in the interferon/ribavirin resistance-determining region. LDLT was performed because very high sensitivity to interferon treatment was predicted. Discussion Six months after LDLT and uneventful post-LDLT courses, pegylated interferon-α2a and ribavirin were administered under immunosuppression with cyclosporine and mycophenolate mofetil. This regimen was continued for 48 weeks, resulting in a viral response at 10 weeks and a sustained viral response, as predicted.

Conclusions We have reported the usefulness of molecular analyses of host and viral factors for indicating LDLT to treat hepatitis C in a borderline case.

Original languageEnglish
Pages (from-to)2426-2429
Number of pages4
JournalTransplantation Proceedings
Volume46
Issue number7
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Living Donors
Hepatitis C
Liver Transplantation
Interferons
Ribavirin
Antiviral Agents
Genotype
Tissue Donors
Mycophenolic Acid
Mutation
Esophageal and Gastric Varices
Liver
Ascites
Liver Cirrhosis
Immunosuppression
Cyclosporine
Therapeutics
Viruses
Transplants

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C : A case report. / Yoshida, Y.; Ikegami, T.; Yoshizumi, T.; Toshima, T.; Yamashita, Y. I.; Yoshiya, S.; Shirabe, K.; Maehara, Y.

In: Transplantation Proceedings, Vol. 46, No. 7, 01.09.2014, p. 2426-2429.

Research output: Contribution to journalArticle

Yoshida, Y. ; Ikegami, T. ; Yoshizumi, T. ; Toshima, T. ; Yamashita, Y. I. ; Yoshiya, S. ; Shirabe, K. ; Maehara, Y. / Rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C : A case report. In: Transplantation Proceedings. 2014 ; Vol. 46, No. 7. pp. 2426-2429.
@article{5a50f5b3527d433190515c2e67b36331,
title = "Rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: A case report",
abstract = "Introduction Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. However, it has never been reported that pre-LDLT genetic analyses of both host and virus, with prediction of the outcome of post-LDLT antiviral treatment, indicated LDLT for a borderline case.Case Report We have reported the case of a 68-year-old woman with liver cirrhosis caused by genotype 1b hepatitis C, a history of ruptured esophageal varices, and adequately controlled minor ascites. Her liver function was classified as Child-Pugh grade B. The donor was a 42-year-old woman with an estimated left lobe graft volume (GV) of 33.8{\%} based on the standard liver volume of the recipient. Molecular analyses used to confirm the indication of LDLT for this combination revealed the following: The rs8099917 genotype was T/T in the donor and recipient, the HCV core protein was double wild type, there were no mutations in the interferon sensitivity-determining region, and 8 mutations were found in the interferon/ribavirin resistance-determining region. LDLT was performed because very high sensitivity to interferon treatment was predicted. Discussion Six months after LDLT and uneventful post-LDLT courses, pegylated interferon-α2a and ribavirin were administered under immunosuppression with cyclosporine and mycophenolate mofetil. This regimen was continued for 48 weeks, resulting in a viral response at 10 weeks and a sustained viral response, as predicted.Conclusions We have reported the usefulness of molecular analyses of host and viral factors for indicating LDLT to treat hepatitis C in a borderline case.",
author = "Y. Yoshida and T. Ikegami and T. Yoshizumi and T. Toshima and Yamashita, {Y. I.} and S. Yoshiya and K. Shirabe and Y. Maehara",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2013.09.059",
language = "English",
volume = "46",
pages = "2426--2429",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C

T2 - A case report

AU - Yoshida, Y.

AU - Ikegami, T.

AU - Yoshizumi, T.

AU - Toshima, T.

AU - Yamashita, Y. I.

AU - Yoshiya, S.

AU - Shirabe, K.

AU - Maehara, Y.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Introduction Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. However, it has never been reported that pre-LDLT genetic analyses of both host and virus, with prediction of the outcome of post-LDLT antiviral treatment, indicated LDLT for a borderline case.Case Report We have reported the case of a 68-year-old woman with liver cirrhosis caused by genotype 1b hepatitis C, a history of ruptured esophageal varices, and adequately controlled minor ascites. Her liver function was classified as Child-Pugh grade B. The donor was a 42-year-old woman with an estimated left lobe graft volume (GV) of 33.8% based on the standard liver volume of the recipient. Molecular analyses used to confirm the indication of LDLT for this combination revealed the following: The rs8099917 genotype was T/T in the donor and recipient, the HCV core protein was double wild type, there were no mutations in the interferon sensitivity-determining region, and 8 mutations were found in the interferon/ribavirin resistance-determining region. LDLT was performed because very high sensitivity to interferon treatment was predicted. Discussion Six months after LDLT and uneventful post-LDLT courses, pegylated interferon-α2a and ribavirin were administered under immunosuppression with cyclosporine and mycophenolate mofetil. This regimen was continued for 48 weeks, resulting in a viral response at 10 weeks and a sustained viral response, as predicted.Conclusions We have reported the usefulness of molecular analyses of host and viral factors for indicating LDLT to treat hepatitis C in a borderline case.

AB - Introduction Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. However, it has never been reported that pre-LDLT genetic analyses of both host and virus, with prediction of the outcome of post-LDLT antiviral treatment, indicated LDLT for a borderline case.Case Report We have reported the case of a 68-year-old woman with liver cirrhosis caused by genotype 1b hepatitis C, a history of ruptured esophageal varices, and adequately controlled minor ascites. Her liver function was classified as Child-Pugh grade B. The donor was a 42-year-old woman with an estimated left lobe graft volume (GV) of 33.8% based on the standard liver volume of the recipient. Molecular analyses used to confirm the indication of LDLT for this combination revealed the following: The rs8099917 genotype was T/T in the donor and recipient, the HCV core protein was double wild type, there were no mutations in the interferon sensitivity-determining region, and 8 mutations were found in the interferon/ribavirin resistance-determining region. LDLT was performed because very high sensitivity to interferon treatment was predicted. Discussion Six months after LDLT and uneventful post-LDLT courses, pegylated interferon-α2a and ribavirin were administered under immunosuppression with cyclosporine and mycophenolate mofetil. This regimen was continued for 48 weeks, resulting in a viral response at 10 weeks and a sustained viral response, as predicted.Conclusions We have reported the usefulness of molecular analyses of host and viral factors for indicating LDLT to treat hepatitis C in a borderline case.

UR - http://www.scopus.com/inward/record.url?scp=84908207957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908207957&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2013.09.059

DO - 10.1016/j.transproceed.2013.09.059

M3 - Article

C2 - 25150603

AN - SCOPUS:84908207957

VL - 46

SP - 2426

EP - 2429

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -